Odyssey TherapeuticsODTX +2.01%9 9-Day RSI is 63.59 as of Jun. 30, 2026. GuruFocus rates ODTX with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Odyssey Therapeutics ranks worse than 75.97% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Odyssey Therapeutics 9-Day RSI Related Terms
ODTX vs VOR, PHAT, GERN: 9-Day RSI Comparison
For the Biotechnology subindustry, Odyssey Therapeutics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Odyssey Therapeutics 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Odyssey Therapeutics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Odyssey Therapeutics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Odyssey Therapeutics (ODTX) has a 9-Day RSI of 63.59 as of Jun. 30, 2026. According to the industry distribution chart, Odyssey Therapeutics ranks #1081 out of 1423 companies in the Biotechnology industry, placing it in the top 76%.
Is Odyssey Therapeutics' 9-Day RSI too high?
Odyssey Therapeutics' current 9-Day RSI is 63.59. The Biotechnology industry median 9-Day RSI is 50.00. Odyssey Therapeutics' value of 63.59 is 27.2% above this industry median. Based on the distribution chart, Odyssey Therapeutics ranks #1081 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Odyssey Therapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' 9-Day RSI compare to VOR and PHAT?
According to the Biotechnology industry distribution chart, Odyssey Therapeutics ranks #1081 out of 1423 companies for 9-Day RSI. This places Odyssey Therapeutics in the lower half of its industry. The industry median 9-Day RSI is 50.00. Odyssey Therapeutics' value of 63.59 is 27.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.00, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Odyssey Therapeutics's current 9-Day RSI of 63.59 is 27.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Odyssey Therapeutics's current 9-Day RSI is 63.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current 9-Day RSI of 63.59. The current 9-Day RSI is 63.59 and 27.2% above the Biotechnology industry median of 50.00. Odyssey Therapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current 9-Day RSI is 63.59 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
9GF Score
Get the complete analysis for ODTX
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ODTX has been successfully added to your 